From the Department of Neurology (V.P., K.S., T.P.), Aarhus University Hospital; Department of Neurology (Z.I., H.H.N.), Odense University Hospital; Institute of Clinical Research (Z.I., H.H.N.), Institute of Molecular Biology (H.H.N.), and Department of Regional Health Research, Faculty of Health Sciences (E.S.), University of Southern Denmark, Odense; The Danish Multiple Sclerosis Center (M.M., P.E.H.J., F.S.), Department of Neurology, Rigshospitalet, University of Copenhagen; The Danish Multiple Sclerosis Registry (M.M., N.K.-H.), Department of Neurology, Rigshospitalet, Copenhagen University Hospital; Department of Clinical Epidemiology, Clinical Institute (N.K.-H.), and Department of Biomedicine (T.C.), Aarhus University; MS-Clinic of Southern Jutland (Sønderborg, Esbjerg, Kolding) (M.K., E.S.), Department of Neurology, Hospital of Southern Jutland, Sønderborg; Department of Neurology (C.C.P., Z.M.), Aalborg University Hospital; Multiple Sclerosis Unit (S.F.R.), Department of Neurology, Herlev Hospital, Copenhagen; Department of Neurology (M.B.J.), Nordsjællands Hospital, Hillerød; Department of Neurology (A.E.P.), Hospital of Southwest Jutland, Esbjerg; Department of Neurology (L.R.), Hospital of Central Denmark Region, Viborg; Department of Autoimmunology and Biomarkers (M.C.L., N.H.), Statens Serum Institut, Copenhagen; and Department of Neurology (J.L.F.), Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Denmark.
Neurology. 2018 Dec 11;91(24):e2265-e2275. doi: 10.1212/WNL.0000000000006645. Epub 2018 Nov 9.
To estimate the nationwide population-based incidence, prevalence, and geographical distribution of neuromyelitis optica (NMO) spectrum disorder (NMOSD) in Denmark based on the 2015 International Panel for NMO Diagnosis (IPND) criteria.
We conducted a multicentre, historically prospective study. Data were sourced from the Danish National Patient Registry, the Danish Multiple Sclerosis Registry, departments of neurology, and laboratories providing aquaporin-4 antibody test. Cases were selected based on the 2006 Wingerchuk and the 2015 IPND criteria and were individually validated by an expert panel.
We confirmed NMO in 30 cases (2006 criteria) and NMOSD in 56 cases (2015 IPND criteria) between 2007 and 2014. Defined by the 2006 criteria, the incidence of NMO was 0.029 per 100,000 person-years (95% confidence interval [CI] 0.014-0.051), and the prevalence (aged 16 years and older) was 0.566 per 100,000 (95% CI 0.370-0.830). Based on the 2015 IPND criteria, the incidence of NMOSD was 0.070 per 100,000 person-years (95% CI 0.046-0.102), and the prevalence (aged 16 years and older) was 1.09 per 100,000 (95% CI 0.808-1.440), without regional differences.
Our estimates of incidence and prevalence are similar to other Caucasian population-based studies using the 2015 IPND criteria. We found no geographical clustering in Denmark.
根据 2015 年国际视神经脊髓炎诊断小组（IPND）标准，估算丹麦全国基于人群的视神经脊髓炎（NMO）谱系障碍（NMOSD）的发病率、患病率和地理分布。
我们开展了一项多中心、历史性前瞻性研究。数据来源于丹麦国家患者登记处、丹麦多发性硬化症登记处、神经病学科室和提供水通道蛋白-4 抗体检测的实验室。根据 2006 年 Wingerchuk 和 2015 年 IPND 标准选择病例，并由专家组进行单独验证。
我们在 2007 年至 2014 年间确诊了 30 例（2006 标准）和 56 例（2015 IPND 标准）NMOSD。按照 2006 年标准，NMO 的发病率为 0.029/10 万人年（95%可信区间 [CI]：0.014-0.051），患病率（年龄≥16 岁）为 0.566/10 万人（95%CI：0.370-0.830）。基于 2015 年 IPND 标准，NMOSD 的发病率为 0.070/10 万人年（95%CI：0.046-0.102），患病率（年龄≥16 岁）为 1.09/10 万人（95%CI：0.808-1.440），无地域差异。
我们的发病率和患病率估计与使用 2015 年 IPND 标准的其他白种人基于人群的研究相似。在丹麦未发现地理聚集性。
